You are on page 1of 2

MOBILE App IN STORE!

Friday 18 Sep 2015

healthnotes.com.au

PHARMACYDAILY.COM.AU

New PCEHR name

Truss backs pharmacy

PSA urges biosimilar clarity

Health minister Sussan Ley has


formally introduced legislation into
parliament which will change the
name of the Personally Controlled
Electronic Health Record to My
Health Record.
The bill also introduces the
concept of automatic opt-in.

Deputy prime minister Warren


Truss has confirmed the strong
with the Society urging that a
The Pharmaceutical Society of
support from the federal National
Australia is offering its expertise
consensus Australian document
Party for community pharmacy,
on terminology and definitions
to the government to provide
with Truss highlighting the critical
relating to biologicals be
education, practice support and
role of pharmacists in regional
developed as a priority, to
communication materials on
AVAILABLE
NOW IN PHARMACIES
Australia at a Guild-sponsored
provide accurate and common
biosimilars
for the pharmacy
business lunch in Canberra last week.
profession, in consideration of
understanding.
The PSA is suggesting the
possible long-term impacts of
establishment of a stakeholder
biological medicines generally, but
biosimilar medicines in particular.
group to determine appropriate
parameters, which may
In a new position statement on
*
With many years of international dermatological
company
Stratpharmainclude
has developed
breakthrough
treatments for
an extension
of routine
biosimilarsexpertise,
issued Swiss
yesterday,
PSA
faster wound healing, abnormal scarnational
preventionpresident
and treatment,
are now availablepharmacovigilance
in over 50 countries. These
silicone-based
requirements.
Joe that
Demarte
products are clinically proven to be effective and easy to use alone or in combination with more invasive therapies.
Pharmacists have a fundamental
said pharmacists currently follow
The first film-forming
For the prevention and
substitution principles which
role in pharmacovigilance
silicone gel based
treatment of hypertrophic
activities...there is an imperative
respect the choice of prescribers
wound dressing
scars and keloids
to capitalise on the pharmacists
and patients, in accordance
approved for use
medicines expertise and frontline
with PSAs Professional Practice
on open wounds and
nnccceee
health professional role,
Standards and Guidelines for
ooonDemarte
compromised skin
y
y
y
l
l
l
i
i
i
said, urging a national awareness
Pharmacists on PBS Brand
dddaaa
e
campaign on biosimilars based
Substitution.
onc y For
For
Forthe
the
theprevention
prevention
preventionand
and
andtreatment
treatment
treatmentof
of
ofhype
hyp
hyp
around
clear
and
consistent
PSA believes a holistic, nationallyi
Stratamed is the first film-forming silicone gel-based
a l trophic
trophic
trophicscars
scars
scarsand
and
andkeloids
keloids
keloids
d
approved for use
on open wounds
communication
messages
to and
coordinated and outcomes- wound dressing
Silicone
Silicone
Siliconegel
gel
gelisisisinternationally
internationally
internationallyrecommended
recommende
recommend
skin
For
the
prevention
trea
* and
support
prescribers, pharmacists
focused approach is essential compromised
gold
gold
goldstandard
standard
standard
inininnon-invasive
non-invasive
non-invasive
scar
scar
scar
treatme
treatm
treatm
trophic
scars
and
keloids
immediately
after skin resurfacing (laser
and
patients.
for a strong pharmacovigilance Can be used
For
For
Forboth
both
bothold
old
oldand
and
andnew
new
newscars
scars
scars
treatment, chemical peels, dermal abrasion, tattoo
removal
Silicone gel is international
Linear
Linear
Linear
hypertrophic
hypertrophic
hypertrophic
scar
scar
scar
22 2
View
theand
paper
psa.org.au.
program in relation to biosimilars,
Prevents
Prevents
Preventsabnormal
abnormal
abnormal
scar
scarformation
formation
formation
after
after
after
nevis
nevis
nevis
extraction
extraction
extraction
etc), general,
cosmetic
Mohsat
surgery,
trauma,
burns
goldscar
standard
in non-invasi

Stratpharma has wound healing covered

44 4

(1st and 2nd degree)

Age
Age
Age
ofofof
scars
scars
scars
before
before
before
treattreattreatment:
ment:
ment:
14
1414
months
months
months

Bacteriostatic, gas permeable and inert1

MA assures on trials
Vitamins & audio loss
Creates an optimal environment for faster wound healing,

Left
Left
Left
scar
scar
scar
remained
remained
remained
untreated
untreated
untreated

33 3
Softens
Softens
Softensand
and
andflattens
flattens
raised
raised
raised
scars
scars
flattens
For both
oldscars
and
new scars

Linear hypertrophic scar


after nevis extraction4

33 3
Relieves
Relieves
Relievesitching
itching
itching
and
and
anddiscomfort
discomfort
discomfort
Prevents
abnormal scar for

STRATAMED ADVANCED WOUND


33 3
Reduces
Reduces
Reducesredness
redness
redness
and
and
anddiscolouration
discolouration
discolouration
* Softens
and flattens raised
DRESSING 5G,
RRP $26.95

Age of scars before treatment: 14 months

reduced downtime
Medicines Australia yesterdayresulting in Higher
intakes of -carotene,
STRATADERM
SCAR THERAPY GEL
Linear
Linear
Linear
hypertrophic
hypertrophic
hypertrophic
scar
scar
scar
Can
Can
Canbe
be
beused
used
usedinin
monotherapy
monotherapy
monotherapy
or
oror
ininincombina
combin
combi
Left scar remained
Laser resurfacing (acne scars)
inRelieves
itching
and
discom
after
after
after
trauma
trauma
trauma
untreated
11 1
inflammatory response
-cryptoxanthin
and1 folate are
(Left)
with
with
withmore
more
moreinvasive
invasive
invasive028100
therapy
therapy
therapy
5G,Before
RRPtreatment
$21.95(Middle) Day 0 (Right) Day 7 issued a statement expressing Reduces the
Sigma
PDE
Before
Before
Before
treatment
treatment
treatment

After
After
22months
2months
months
treatment
treatment
treatment
1After

44 4

Sigma PDE 862904


Symbion PDE 197122
STRATADERM SCAR THERAPY GEL
10G, RRP $32.95

Sigma PDE 862912


Symbion PDE 197025
For any queries, please call

1800 567 007

or email marissa@bsaus.com.au

Reduces redness and disco


Before
treatmentrisk of
After
2 months
treatment
concerns about a Financial Review
Provides symptomatic
(redness/discoloration,
associatedrelief
with
lower
ment:
ment:
ment:
22itching,
weeks
2weeks
weeks
Suitable
Suitable
Suitablefor
for
for
children
children
children
or
ororpeople
people
peoplewith
with
with
Symbion
PDE
197092
1
Linear
hypertrophic
scar
pain) loss, whereas higher
sensitive
sensitive
sensitiveskin
skin
skin Can be used in monotherap
report which it says brings into discomfort,hearing
after trauma
with more invasive therapy
Hydrates and
protects
and compromised
Age of scar before treatquestion the safety and ethics of
vitamin
C superficial
intakeAfter
is3wounds
associated
with
STRATAMED ADVANCED
WOUND
After
After
3months
3months
months
treatment
treatment
treatment
Before
Before
Before
treatment
treatment
treatment
ment: 2 weeks
Suitable for children or peo
skin1
clinical trials.
higher risk, according to a US study
*sensitive
DRESSING10G,
RRP
$39.95
skin
Improves the visible outcome of the treatment3
The AFR report describes the RIAT
published in the American Journal
Sigma PDE 028118
After 3 months treatment
Before treatment
Easy to apply
with a great
safety
profile1
(Restoring Invisible and Abandoned
of Clinical
Nutrition.
Symbion
PDE 197165
www.stratamed.com
Trials) initiative of the British
Data from 65,521 women in the
*Formerly named Stratamed medical
Medical Journal which re-analyses
Nurses Health Study II from 1991
use scar therapy gel
clinical trial data.
to 2009, representing 1,084,598
person-years of follow-up, revealed
eMA said without the support of
For any queries, please call
oncinnovative
medicine companies
12,789 hearing loss cases.
Laser
Laser
Laser
resurfacing
resurfacing
resurfacing
(acne
(acne
(acne
scars)
scars)
scars)
ily trials would not go ahead
Flexible
Flexible
Flexiblesilicone
silicone
siliconewound
wound
wounddressing
dressing
dressingfor
for
forfaste
fast
fas
No
significant
risk
trend
with
Stratamed
Stratamed
Stratamed
inincombination
incombination
combination
with
with
with
thermage
thermage
thermage
and
and
and
CO
COCO
fractional
fractional
fractional
laser
laser
laser
resurfacing
resurfacing
resurfacing
damany
wound
wound
woundhealing
healing
healingand
and
andabnormal
abnormal
abnormalscar
scar
scarprevent
preven
preve
Stratadermintake
- for the
treatment
of
meaning more effective medicines
ofprevention
vitamin Eand
was
observed.
For the prevention
and treatment
of hyperoremail
marissa@bsaus.com.au
Approved
Approved
Approved
to
totouse
use
useon
on
onopen
open
openwounds
wounds
woundsand
and
and
hypertrophic
scars
keloids
Laserthe
resurfacing
(acne scars)
would be unavailable.
CLICKandHERE
for
abstract.
Flexible
trophic scars and keloids
compromised
compromised
compromised
skin
skin
skin silicone wound dre
Stratamed in combination with thermage and CO fractional laser resurfacing
Age
Age
Age
ofofof
scar
scar
scar
before
before
before
treattreattreat-

Class
Class
Class
I Medical
I Medical
I Medical
Device
Device
Device
FDA
FDA
FDA
Listed/TGA
Listed/TGA
Listed/TGA
Registered
Registered
Registered

1.1.
Gold
1.
Gold
Gold
MH
MH
et
MH
et
al.et
al.
Dermatol
al.
Dermatol
Dermatol
Surg
Surg
Surg
2014;40:817824
2014;40:81782
2014;40:817
2.2.
Monstrey
2.
Monstrey
Monstrey
S et
S et
Sal.et
al.
JPRAS
al.
JPRAS
JPRAS
2014;19
2014;19
2014;19
3.3.
Tobola
3.
Tobola
Tobola
J. Dermat
J. Dermat
J. Dermat
Estetyczna
Estetyczna
Estetyczna
2004;35(6):323328
2004;35(6):3233
2004;35(6):323
4.4.
Data
4.
Data
Data
onon
file.
on
file.
file.
Stratpharma
Stratpharma
Stratpharma
AGAGAG

Class I Medical Device


FDA Listed/TGA Registered

1. Gold MH
2. Monstre
3. Tobola
4. Data on

1800 567 007

11 1

22 2

Silicone gel is internationally recommended as a gold


wound healing and abnorm
1,2
1,2
1,2
Silicone gel is internationally
as treatment4
Bacteriostatic
Bacteriostatic
Bacteriostaticand
and
andinert
inert
inert
standard inrecommended
non-invasive scar
Approved to use on open
gold standard in non-invasive scar treatment1
Provides
Provides
Providessymptomatic
symptomatic
symptomatic
relief
relief
relief
(redness/
(redness/
Before
Before
Before
treatment
treatment
treatment
During
During
treatment
treatment
treatment
Day
Day
Day
77 7
For both old and
new
scars During
compromised(redness/
skin
For both old and new scars
discolouration,
discolouration,
discolouration,itching,
itching,
itching,discomfort,
discomfort,
discomfort,pain)
pain)
pain
5

Prevents
abnormal
scar
formation
Domestic
Domestic
Domestic
2
2
2
degree
degree
degree
burn
burn
burn
on
on
on
a
a
foot
a
foot
foot
Linear hypertrophic
scar

Bacteriostatic
and
inert1,2
1
2
Linear hypertrophic scar 14 months after excision (nevis
Monotherapy
Monotherapy
Monotherapy
with
with
with
Stratamed
Stratamed
Stratamed
Prevents abnormal scar formation
after excision)
nevis extraction
Domestic
2nd
degree
burn on a foot1

Can
Can
Can
be
be
be
used
used
used
immediately
immediately
immediately
after
after
after
dermatolo
dermatolo
dermato
6
Softens and flattens raised scars
general
Provides
symptomatic
reli
Age of scars before treatBefore treatment
During treatment
Day 7
interventions,
interventions,
interventions,
general
generaland
and
and
Mohs
Mohs
Mohssurgery,
surgery
surger
Softens and flattens raised scars3
ment: 14 months
discolouration,
itching, di
6
ststst
nd
ndnd
Relieves itching
and
discomfort
and
and
and
2
2
2
degree
degree
degree
burns
burns
burns
trauma,
trauma,
trauma,
1
1
1
Domestic 2 degree burn on a foot
Left scar remained
Relieves itching and discomfort3
Monotherapy with Stratamed
untreated
with
Can
usedsafety
immediately
Reduces redness and
discoloration6
Easy
Easy
Easyto
totoapply
apply
apply
with
withaabe
agreat
great
great
safety
safetyprofile
profile
profil1
3
interventions, general and

Reduces
redness
and
discolouration
Before treatment
After 2 months treatment
Can be used in monotherapy or in combination with more
st
nd
Suitable
Suitable
Suitablefor
for
forchildren
children
children
or
ororpeople
people
with
and with
2with
degre
trauma,
1people
Before treatment.
AfterLinear
2 months
of monotherapy
treatment
withbe
Strataderm.
hypertrophic
scar
Can
used in monotherapy
orBefore
in
4combination
Linear hypertrophic scar (after nevis excision)
sensitive
sensitive
sensitiveskin
skin
skin
invasive therapy
Before
Before
treatment
treatment
treatment
Day
Day
22 22
Day
Day
Day
16
16
Before
treatment Day
Day
Day
1616after monotherapy with Stratamed
after
Left
scar trauma
remained
untreated.
(Left) Before treatment, 14 months after excision
(Right)
After 2 months
of monotherapy
Easy to apply with a grea
with more invasive therapy1
Age of scar before treatwww.strataderm.com
treatment with Strataderm
ment: 2 weeks and treatment of
New generation silicone gel for the prevention
scars for children or people with
Flexible silicone wound dressing for faster wound healing and abnormal
scar
prevention
Class
Class
Class
IIaIIaMedical
IIaMedical
Medical
Device
Device
Device
Suitable
for children or p
Suitable
FDA
FDA
FDA
Listed/TGA
Listed/TGA
Listed/TGA
Registered
Registered
Registered
sensitive skin
sensitive skin
Day 2 and compromised
Day 16 skin
Once daily application
Approved toBefore
use treatment
on open wounds
2

ndnd nd

33 3

nd

1.1.
Sandhofer
1.
Sandhofer
Sandhofer
M,M,
Schauer
M,
Schauer
Schauer
P. P.
Skinmed
Skinmed
P. Skinmed
2012;
2012;
2012;
10(6):1
10(6)
10(
2.2.
Monk
2.
Monk
Monk
ECEC
etEC
et
al.et
al.
Dermatol
al.
Dermatol
Dermatol
Surg
Surg
Surg
2014;
2014;
2014;
40:7679
40:7679
40:767
3.3.
Data
3.
Data
Data
onon
file.
on
file.
file.
Stratpharma
Stratpharma
Stratpharma
AGAGAG

For both old and new scars


Before treatment

After 3 months treatment

Class I Medical Device


FDA Listed/TGA Registered

References: (1) Data on file. Stratpharma AG

Switzerland

Easy to apply with a great safety profile2

1. Gold MH et al. Dermatol Surg 2014;40:817824


2. Monstrey S et al. JPRAS 2014;19
3. Tobola J. Dermat Estetyczna 2004;35(6):323328
4. Data on file. Stratpharma AG

References: (1)For
Data more
on file. Stratpharma
AG
(2) Sandhofer
M, Schauer
Sponsor
Sponsor
Sponsor
ininAustralia:
in
Australia:
Australia:
information:
1800 567
007 P. SKINmed 2012;10:S1S7.

Manufactured
Manufactured
Manufactured
by:
by:
by:
Stratpharma
Stratpharma
Stratpharma
AG,
AG,
AG,
Centralbahnplatz
Centralbahnplatz
Centralbahnplatz
88 8
CH-4051
CH-4051
CH-4051
Basel,
Basel,
Basel,
Switzerland
Switzerland
Switzerland

Class IIa Medical Device


FDA Listed/TGA Registered

A AL ALKerr
Kerr
L Kerr
Medical
Medical
Medical
Pty
Pty
Pty
Ltd,
Ltd,
Ltd,
174
174
174
Willoughby
Willoughby
Willoughby
Road
Road
Road
Crows
Crows
Crows
Nest
Nest
Nest
NSW
NSW
NSW
2065,
2065,
2065,
Tel:
Tel:
Tel:
1800
1800
1800
567
567
567
007
007
007

174 Willoughby Rd, Crows Nest, NSW 2065 Australia www.stratpharma.com

Swit
Sw
S

For any queries, please call 1800 567 007 or email marissa@bsaus.com.au

in Australia:
by:Surg 2014;40:817-824.Sponsor
References: (1) Sandhofer M, Schauer P. SKINmed 2012;10:S1S7. (2) Monk EC, Benedetto EA, Benedetto AV. Dermatologic Surgery 2014;40;7679. (3) Data on file. Stratpharma AG (4) Gold MHManufactured
et al. Dermatol
(5) Monstrey
S et
A L Kerr Medical Pty Ltd, 174 Willoughby Road
Stratpharma AG, Centralbahnplatz 8
al. JPRAS 2014;1-9. (6) Dermat Estetyczna 2004;35(6):323-328

Pharmacy Daily Friday 18th September 2015

t 1300 799 220

CH-4051 Basel, Switzerland

Crows Nest NSW 2065, Tel: 1800 567 007

w www.pharmacydaily.com.au

1. Sandho
2. Monk E
3. Data on

page 1

IS THE INFORMATION YOU HAVE ON DOSING


FOR CHILDREN RELEVANT & UP TO DATE?

Part
of th
Phar e
m
Board acy
of
Aust
ra
Requ lias
ired
Text
List

Friday 18 Sep 2015

Events Calendar
WELCOME to Pharmacy
Dailys events calendar,
opportunities to earn CPE and
CPD points.
If you have an upcoming event
youd like us to feature, email
info@pharmacydaily.com.au.
17-19 Sep: Pharmacy Business
Network; Etihad Stadium,
Melbourne; details at:
pharmacybusinessnetwork.com
19 Sep: PSA Immunisation
Training; St Leonards; visit:
www.psa.org.au
22 Sep: Excellence in Allergic
Rhinitis CPD Seminar and
Webcast; The Arena - NAB
Docklands, Vic; more info at:
www.guild.org.au
7 Oct: Understanding the NES
and Your Award; Brisbane; info
and registration:
www.guild.org.au/qldcpd
14 Oct: Pharmacy Business
Insight (PBI) Workshop:
Building a more sustainable
healthcare business for your
community; Melbourne; info
and rego: pbiworkshop.com.au
15-17 Oct: The Pharmacy
Assistant National Conference;
QT Gold Coast; details at:
www.pharmacyassistants.com
23-24 Oct: Blackmores Institute
Symposium 2015; Pullman
Melbourne Albert Park; visit:
www.ivvy.com/event/BIS15

PHARMACYDAILY.COM.AU

(online & print)

THE LATEST EDITION IS AVAILABLE NOW

Biostime acquires Swisse


Hong Kong-listed Biostime and
vitamin maker Swisse Wellness
announced last night they have
reached a binding heads of
agreement with Biostime taking
an 83% interest in Swisse with an
investment of A$1.67 billion.
The founding Ring family and
management team led by chief
executive Radek Sali are expected
to keep a 15 - 20% stake in the
business, the AFR reports.
Biostime, founded in 1999, is
one of the leading premium infant
formula, baby food and baby care
producers in Asia with more than
200 sales offices across China and
revenues of RMB 4,732m (A$934m)
in FY14.
Headquartered in Guangzhou,
China, Biostime employs more than
3,300 people.
Biostime will enhance China-wide
distribution, increase e-commerce
capability and will bring a wellestablished customer loyalty
program to the partnership, Swisse
said.
Swisse Wellness ceo Radek
Sali will continue to lead Swisse
Wellness, and alongside the
Executive team and existing
shareholders, will remain invested
in the business; he will also join the
Biostime Board.
Swisses founding shareholder
Stephen Ring said, I am incredibly
proud to have been part of Swisses
journey so far.

The strength of the business


is testament to the hard work,
passion and energy of the entire
Swisse team and I thank them for
their ongoing commitment to the
business.
Biostime ceo Lui Fei released
a statement saying, The Swisse
brand is synonymous with
Australias clean, green and healthy
lifestyle and the quality and
premium positioning of the brand.
Swisse has strong appeal
to Chinese consumers and is
considered a leading VHMS brand.
The escalating demand from
China has also driven a five-fold
jump in the share price of Swisses
listed peer Blackmores over the
past 12 months.
With Australia considered a
core market for Swisse Wellness,
the company will remain
headquartered in Melbourne, Sali
said.

FDA bans Camels


The US Food and Drug
Administration has banned four RJ
Reynolds cigarette brands including
Camel Crush Bold because a
science based review found they
were not substantially equivalent to
respective predicate products.

DISPENSARY
CORNER
NA-NA NA-NA, na-na na-na,
BATBAND!
Not sure that the theme music
translates too well into text, but
you probably get the idea, and
yes there is in development such
a thing.
Its actually a set of headphones
that bypass your ears, leaving
them to still hear surrounds in
stereo, while listening to your
favourite music, podcasts or
audiobooks via skull bone
transduction (pictured).

Called ear-free headphones,


the Batband was fully funded on
Kickstarter in just seven days, and
will remain on the crowd-funding
website until 28 Oct.
As of yesterday, there were 1,326
backers for the project who have
pledged a total of $228,429, a
huge overshoot of the $150K goal.
CLICK HERE to join the party.

Give your feet some love!


This week Pharmacy Daily and Plunketts are giving away a prize pack each
day of NS-8 Heel Balm, NS-8 Foot & Leg Moisturiser
and NS-8 Foot & Shoe Deodoriser.
Spring is here and its time to make sure your feet are
ready soft, smooth and odour-free. NS-8 Natural
Footcare formulations are based on carefully selected
naturally active ingredients to deliver superior results.
NS-8 Heel Balm is not greasy, so you dont need socks,
and natural exfoliants gradually remove dry, thickened
skin, so you dont need foot files. NS-8 Foot & Leg Moisturiser refreshes and
moisturises hot, tired legs, softening and smoothing dry skin. NS-8 Foot &
Shoe Deodoriser is a non-aerosol spray that kills odour causing bacteria on
shoes and feet. Australian owned and made. Website: www.NS8.com.au
To win, be the first person from TAS or VIC to answer the following
question and send it to comp@pharmacydaily.com.au

Does NS-8 Foot & Shoe Deodoriser contain aluminium?


Congratulations to yesterdays winner, Rebecca Larcombe from Flinders Medical Centre.
Pharmacy Daily is Australias favourite pharmacy industry publication.
Sign up free at www.pharmacydaily.com.au.
Postal address: PO Box 1010, Epping, NSW 1710 Australia
Street address: 4/41 Rawson St, Epping NSW 2121 Australia
P: 1300 799 220 (+61 2 8007 6760) F: 1300 799 221 (+61 2 8007 6769)

Publisher: Bruce Piper info@pharmacydaily.com.au


Reporter: Mal Smith
Advertising and Marketing: Magda Herdzik advertising@pharmacydaily.com.au
Business Manager: Jenny Piper accounts@pharmacydaily.com.au

Part of the Travel Daily group of publications.


business events news
Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of
the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.